What is Zacks Research's Forecast for TEVA Q4 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Analysts at Zacks Research decreased their Q4 2025 earnings per share estimates for Teva Pharmaceutical Industries in a research report issued on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will earn $0.66 per share for the quarter, down from their prior forecast of $0.75. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.77 EPS, Q4 2026 earnings at $0.68 EPS and FY2027 earnings at $2.73 EPS.

Several other brokerages also recently weighed in on TEVA. Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday. Finally, Bank of America decreased their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of TEVA traded down $0.01 during mid-day trading on Thursday, hitting $15.34. 11,322,175 shares of the company's stock were exchanged, compared to its average volume of 12,799,828. The stock's 50-day moving average is $18.85 and its 200-day moving average is $18.38. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The company has a market cap of $17.40 billion, a price-to-earnings ratio of -10.58, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.55% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Smithfield Trust Co grew its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Finally, Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $60,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.